Loading...
•
Dec 31, 2025
Immunome Q4 2025 Earnings Report
Immunome reported fourth quarter 2025 results with no collaboration revenue and a net loss of 41577000, while adjusted EPS was reported at -0.75.
Key Takeaways
For the fourth quarter of 2025, Immunome reported no collaboration revenue and a net loss of 41577000. Research and development expenses remained elevated as the company advanced its oncology pipeline. Adjusted EPS for the quarter was -0.75.
No collaboration revenue was recorded in Q4 2025.
Net loss for the quarter was 41577000.
Research and development expenses totaled 49193000.
Adjusted EPS was reported at -0.75.
Forward Guidance
The company plans to submit an NDA for varegacestat in the second quarter of 2026 and continue advancing its oncology pipeline, while expecting continued operating losses.
Positive Outlook
- Positive Phase 3 RINGSIDE results for varegacestat.
- Planned NDA submission in Q2 2026.
- Advancing multiple clinical programs.
- Strong cash position at quarter end.
- Ongoing Phase 1 trial for IM-1021.
Challenges Ahead
- Continued quarterly net losses.
- No product revenue generated to date.
- High research and development spending.
- Regulatory approval risk remains.
- Dependence on external capital for long-term funding.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...